Kayode K Ojo

List of Publications by Year
in descending order

96 papers	3,622 citations	117625 34 h-index	155660 55 g-index
102 all docs	102 docs citations	102 times ranked	3194 citing authors

#	Article	IF	Citations
1	Common Molecular Targets of a Quinolone Based Bumped Kinase Inhibitor in Neospora caninum and Danio rerio. International Journal of Molecular Sciences, 2022, 23, 2381.	4.1	5
2	Targeting Pantothenate Kinase as an Effective Strategy for Antifungal Drug Development. FASEB Journal, 2022, 36, .	0.5	0
3	Repurposing the Kinase Inhibitor Mavelertinib for Giardiasis Therapy. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	3
4	One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases. Veterinary Parasitology, 2021, 289, 109336.	1.8	16
5	Pyrrolopyrimidine Bumped Kinase Inhibitors for the Treatment of Cryptosporidiosis. ACS Infectious Diseases, 2021, 7, 1200-1207.	3.8	3
6	A Curious Case for Development of Kinase Inhibitors as Antigiardiasis Treatments Using Advanced Drug Techniques. ACS Infectious Diseases, 2021, 7, 943-947.	3.8	4
7	Repurposing Infectious Disease Hits as Anti-Cryptosporidium Leads. ACS Infectious Diseases, 2021, 7, 1275-1282.	3.8	8
8	In vitro activity, safety and in vivo efficacy of the novel bumped kinase inhibitor BKI-1748 in non-pregnant and pregnant mice experimentally infected with Neospora caninum tachyzoites and Toxoplasma gondii oocysts. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 16, 90-101.	3.4	17
9	Endochin-like quinolones (ELQs) and bumped kinase inhibitors (BKIs): Synergistic and additive effects of combined treatments against Neospora caninum infection in vitro and in vivo. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 17, 92-106.	3.4	7
10	CDPKs: The critical decoders of calcium signal at various stages of malaria parasite development. Computational and Structural Biotechnology Journal, 2021, 19, 5092-5107.	4.1	6
11	Plasmodium falciparum Calcium-Dependent Protein Kinase 4 is Critical for Male Gametogenesis and Transmission to the Mosquito Vector. MBio, 2021, 12, e0257521.	4.1	26
12	Reduced treatment frequencies with bumped kinase inhibitor 1369 are effective against porcine cystoisosporosis. International Journal for Parasitology: Drugs and Drug Resistance, 2020, 14, 37-45.	3.4	3
13	Comparative assessment of the effects of bumped kinase inhibitors on early zebrafish embryo development and pregnancy in mice. International Journal of Antimicrobial Agents, 2020, 56, 106099.	2.5	12
14	The Impact of BKI-1294 Therapy in Mice Infected With the Apicomplexan Parasite Neospora caninum and Re-infected During Pregnancy. Frontiers in Veterinary Science, 2020, 7, 587570.	2.2	7
15	Neospora caninum: Structure and Fate of Multinucleated Complexes Induced by the Bumped Kinase Inhibitor BKI-1294. Pathogens, 2020, 9, 382.	2.8	17
16	Neospora caninum: Differential Proteome of Multinucleated Complexes Induced by the Bumped Kinase Inhibitor BKI-1294. Microorganisms, 2020, 8, 801.	3.6	15
17	Methionyl-tRNA synthetase inhibitor has potent in vivo activity in a novel Giardia lamblia luciferase murine infection model. Journal of Antimicrobial Chemotherapy, 2020, 75, 1218-1227.	3.0	12
18	Taming the Boys for Global Good: Contraceptive Strategy to Stop Malaria Transmission. Molecules, 2020, 25, 2773.	3.8	6

#	Article	IF	Citations
19	Structures of glyceraldehyde 3â€phosphate dehydrogenase in <scp>Neisseria gonorrhoeae</scp> and Chlamydia trachomatis. Protein Science, 2020, 29, 768-778.	7.6	10
20	Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned. International Journal for Parasitology, 2020, 50, 413-422.	3.1	37
21	Treatment with Bumped Kinase Inhibitor 1294 Is Safe and Leads to Significant Protection against Abortion and Vertical Transmission in Sheep Experimentally Infected with Toxoplasma gondii during Pregnancy. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	23
22	Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7015-7020.	7.1	94
23	Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy. Journal of Medicinal Chemistry, 2019, 62, 3135-3146.	6.4	27
24	Bumped kinase inhibitor 1369 is effective against Cystoisospora suis in vivo and in vitro. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 10, 9-19.	3.4	12
25	Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis. Journal of Infectious Diseases, 2019, 219, 1464-1473.	4.0	13
26	Safety and efficacy of the bumped kinase inhibitor BKI-1553 in pregnant sheep experimentally infected with Neospora caninum tachyzoites. International Journal for Parasitology: Drugs and Drug Resistance, 2018, 8, 112-124.	3.4	28
27	Therapeutic Efficacy of Bumped Kinase Inhibitor 1369 in a Pig Model of Acute Diarrhea Caused by Cryptosporidium hominis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	31
28	Kinome chemoproteomics characterization of pyrrolo[3,4-c]pyrazoles as potent and selective inhibitors of glycogen synthase kinase 3. Molecular Omics, 2018, 14, 26-36.	2.8	14
29	In vitro growth inhibition of Theileria equi by bumped kinase inhibitors. Veterinary Parasitology, 2018, 251, 90-94.	1.8	3
30	Toxoplasma Calcium-Dependent Protein Kinase 1 Inhibitors: Probing Activity and Resistance Using Cellular Thermal Shift Assays. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	12
31	7H-Pyrrolo[2,3-d]pyrimidin-4-amine-Based Inhibitors of Calcium-Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1H-Pyrazolo[3,4-d]pyrimidin-4-amine-Based Inhibitors. ACS Infectious Diseases, 2018, 4, 516-522.	3.8	5
32	Screening of the Pathogen Box for inhibitors with dual efficacy against Giardia lamblia and Cryptosporidium parvum. PLoS Neglected Tropical Diseases, 2018, 12, e0006673.	3.0	37
33	Abstract 3837: Bumped kinase inhibitor 1553 selectively inhibits androgen receptor positive prostate cancer. , 2018, , .		0
34	Extended-spectrum antiprotozoal bumped kinase inhibitors: A review. Experimental Parasitology, 2017, 180, 71-83.	1.2	71
35	Two Novel Calcium-Dependent Protein Kinase 1 Inhibitors Interfere with Vertical Transmission in Mice Infected with Neospora caninum Tachyzoites. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	24
36	Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis. Journal of Antimicrobial Chemotherapy, 2017, 72, 2334-2341.	3.0	52

#	Article	IF	Citations
37	5-Aminopyrazole-4-Carboxamide-Based Compounds Prevent the Growth of Cryptosporidium parvum. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	17
38	Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy. Journal of Infectious Diseases, 2017, 215, 1275-1284.	4.0	52
39	In vitro efficacy of bumped kinase inhibitors against Besnoitia besnoiti tachyzoites. International Journal for Parasitology, 2017, 47, 811-821.	3.1	40
40	Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis. International Journal for Parasitology, 2017, 47, 753-763.	3.1	30
41	Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection. Journal of Infectious Diseases, 2017, 216, 55-63.	4.0	44
42	Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond. PLoS Pathogens, 2016, 12, e1005763.	4.7	244
43	Reduced Activity of Mutant Calcium-Dependent Protein Kinase 1 Is Compensated in Plasmodium falciparum through the Action of Protein Kinase G. MBio, 2016, 7, .	4.1	37
44	Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis. Journal of Infectious Diseases, 2016, 214, 1856-1864.	4.0	54
45	Invasion of hepatocytes by Plasmodium sporozoites requires cGMPâ€dependent protein kinase and calcium dependent protein kinase 4. Molecular Microbiology, 2016, 102, 349-363.	2.5	69
46	Selective inhibition of Sarcocystis neurona calcium-dependent protein kinase 1 for equine protozoal myeloencephalitis therapy. International Journal for Parasitology, 2016, 46, 871-880.	3.1	22
47	A Novel Calcium-Dependent Kinase Inhibitor, Bumped Kinase Inhibitor 1517, Cures Cryptosporidiosis in Immunosuppressed Mice. Journal of Infectious Diseases, 2016, 214, 1850-1855.	4.0	29
48	5-Aminopyrazole-4-carboxamide analogues are selective inhibitors of Plasmodium falciparum microgametocyte exflagellation and potential malaria transmission blocking agents. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5487-5491.	2.2	15
49	Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis. Journal of Medicinal Chemistry, 2016, 59, 6531-6546.	6.4	81
50	Bumped kinase inhibitor prohibits egression in Babesia bovis. Veterinary Parasitology, 2016, 215, 22-28.	1.8	19
51	Identification and Validation of Small-Gatekeeper Kinases as Drug Targets in Giardia lamblia. PLoS Neglected Tropical Diseases, 2016, 10, e0005107.	3.0	18
52	Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds. PLoS ONE, 2016, 11, e0149996.	2.5	44
53	Brucella melitensis Methionyl-tRNA-Synthetase (MetRS), a Potential Drug Target for Brucellosis. PLoS ONE, 2016, 11, e0160350.	2.5	21
54	Abstract 3033: Bumped kinase inhibitors: A novel therapy for castration-resistant prostate cancer. , 2016, , .		0

#	Article	IF	Citations
55	In Vitro and In Vivo Effects of the Bumped Kinase Inhibitor 1294 in the Related Cyst-Forming Apicomplexans Toxoplasma gondii and Neospora caninum. Antimicrobial Agents and Chemotherapy, 2015, 59, 6361-6374.	3.2	72
56	A novel CDPK1 inhibitorâ€"a potential treatment for cryptosporidiosis in calves?. Parasitology Research, 2015, 114, 335-336.	1.6	26
57	Theileria equi isolates vary in susceptibility to imidocarb dipropionate but demonstrate uniform in vitro susceptibility to a bumped kinase inhibitor. Parasites and Vectors, 2015, 8, 33.	2.5	25
58	SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of Toxoplasma gondii CDPK1. ACS Medicinal Chemistry Letters, 2015, 6, 1184-1189.	2.8	32
59	Bumped Kinase Inhibitor 1294 Treats Established Toxoplasma gondii Infection. Antimicrobial Agents and Chemotherapy, 2014, 58, 3547-3549.	3.2	66
60	The gatekeeper residue and beyond: homologous calcium-dependent protein kinases as drug development targets for veterinarian Apicomplexa parasites. Parasitology, 2014, 141, 1499-1509.	1.5	47
61	Potent and Selective Inhibitors of CDPK1 from T. gondii and C. parvum Based on a 5-Aminopyrazole-4-carboxamide Scaffold. ACS Medicinal Chemistry Letters, 2014, 5, 40-44.	2.8	49
62	A Specific Inhibitor of PfCDPK4 Blocks Malaria Transmission: Chemical-genetic Validation. Journal of Infectious Diseases, 2014, 209, 275-284.	4.0	83
63	Development of potent and selective Plasmodium falciparum calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria to mosquitoes. European Journal of Medicinal Chemistry, 2014, 74, 562-573.	5.5	54
64	Neospora caninum Calcium-Dependent Protein Kinase 1 Is an Effective Drug Target for Neosporosis Therapy. PLoS ONE, 2014, 9, e92929.	2.5	63
65	A Novel Calcium-Dependent Protein Kinase Inhibitor as a Lead Compound for Treating Cryptosporidiosis. Journal of Infectious Diseases, 2013, 208, 1342-1348.	4.0	67
66	From Onâ€Target to Offâ€Target Activity: Identification and Optimisation of Trypanosoma brucei GSK3 Inhibitors and Their Characterisation as Antiâ€Trypanosoma brucei Drug Discovery Lead Molecules. ChemMedChem, 2013, 8, 1127-1137.	3.2	30
67	Multiple Determinants for Selective Inhibition of Apicomplexan Calcium-Dependent Protein Kinase CDPK1. Journal of Medicinal Chemistry, 2012, 55, 2803-2810.	6.4	60
68	Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5264-5267.	2.2	43
69	Development of Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitors with Potent Anti-Toxoplasma Activity. Journal of Medicinal Chemistry, 2012, 55, 2416-2426.	6.4	101
70	Transmission of malaria to mosquitoes blocked by bumped kinase inhibitors. Journal of Clinical Investigation, 2012, 122, 2301-2305.	8.2	90
71	Structure determination of glycogen synthase kinase-3 from Leishmania major and comparative inhibitor structureâ€"activity relationships with Trypanosoma brucei GSK-3. Molecular and Biochemical Parasitology, 2011, 176, 98-108.	1.1	35
72	Trypanosoma brucei Glycogen Synthase Kinase-3, A Target for Anti-Trypanosomal Drug Development: A Public-Private Partnership to Identify Novel Leads. PLoS Neglected Tropical Diseases, 2011, 5, e1017.	3.0	31

#	Article	IF	Citations
73	Nigeriaâ€™s dracunculiasis eradication triumph and the need for caution. Journal of Infection in Developing Countries, 2011, 5, 901-902.	1.2	1
74	Self-medication with antibiotics for the treatment of menstrual symptoms in southwest Nigeria: a cross-sectional study. BMC Public Health, 2010, 10, 610.	2.9	67
75	Discovery of Potent and Selective Inhibitors of CDPK1 from C. parvum and T. gondii. ACS Medicinal Chemistry Letters, 2010, 1, 331-335.	2.8	126
76	Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. Nature Structural and Molecular Biology, 2010, 17, 602-607.	8.2	172
77	Antimicrobial Use and Resistance in Africa. , 2010, , 301-314.		5
78	Glycogen Synthase Kinase 3 Is a Potential Drug Target for African Trypanosomiasis Therapy. Antimicrobial Agents and Chemotherapy, 2008, 52, 3710-3717.	3.2	86
79	Antimicrobial resistance gene distribution: a socioeconomic and sociocultural perspective. GMS Krankenhaushygiene InterdisziplinÃr, 2008, 3, Doc26.	0.3	2
80	Growing Problem of Multidrug-Resistant Enteric Pathogens in Africa. Emerging Infectious Diseases, 2007, 13, 1640-1646.	4.3	157
81	Tetracycline Resistant Plasmids from UropathogenicEscherichia colifrom Southwestern Nigeria. Journal of Chemotherapy, 2006, 18, 112-114.	1.5	3
82	Antibiotic resistance genes in multidrug-resistantEnterococcusspp. andStreptococcusspp. recovered from the indoor air of a large-scale swine-feeding operation. Letters in Applied Microbiology, 2006, 43, 534-540.	2.2	40
83	CTX-M-15 extended-spectrum Î²-lactamase from Nigerian Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2006, 57, 24-30.	3.0	72
84	Staphylococcus Efflux msr (A) Gene Characterized in Streptococcus , Enterococcus , Corynebacterium , and Pseudomonas Isolates. Antimicrobial Agents and Chemotherapy, 2006, 50, 1089-1091.	3.2	38
85	The presence of a conjugative Gram-positive Tn2009 in Gram-negative commensal bacteria. Journal of Antimicrobial Chemotherapy, 2006, 57, 1065-1069.	3.0	14
86	Characterization of pRAS1-like plasmids from atypical North American psychrophilicAeromonas salmonicida. FEMS Microbiology Letters, 2005, 242, 59-63.	1.8	39
87	Nucleotide sequence and organization of the multiresistance plasmid pSCFS1 from Staphylococcus sciuri. Journal of Antimicrobial Chemotherapy, 2004, 54, 936-939.	3.0	95
88	Distribution and molecular analysis of mef(A)-containing elements in tetracycline-susceptible and -resistant Streptococcus pyogenes clinical isolates with efflux-mediated erythromycin resistance. Journal of Antimicrobial Chemotherapy, 2004, 54, 991-998.	3.0	57
89	The mef (A) Gene Predominates among Seven Macrolide Resistance Genes Identified in Gram-Negative Strains Representing 13 Genera, Isolated from Healthy Portuguese Children. Antimicrobial Agents and Chemotherapy, 2004, 48, 3451-3456.	3.2	65
90	Gram-positivemerAgene in gram-negative oral and urine bacteria. FEMS Microbiology Letters, 2004, 238, 411-416.	1.8	15

#	Article	IF	Citations
91	Gram-positive gene in gram-negative oral and urine bacteria. FEMS Microbiology Letters, 2004, 238, 411-416.	1.8	12
92	Structural analysis of the tetracycline resistance gene region of a small multiresistance plasmid from uropathogenic Escherichia coli isolated in Nigeria. Journal of Antimicrobial Chemotherapy, 2003, 52, 1043-1044.	3.0	10
93	Staphylococcus sciuri Gene erm (33), Encoding Inducible Resistance to Macrolides, Lincosamides, and Streptogramin B Antibiotics, Is a Product of Recombination between erm (C) and erm (A). Antimicrobial Agents and Chemotherapy, 2002, 46, 3621-3623.	3.2	41
94	Identification of a cassette-borne dfrA7-like gene that shows a 97 bp extension at the 3'-end of the reading frame. Journal of Antimicrobial Chemotherapy, 2002, 49, 573-574.	3.0	6
95	Identification of a Complete dfrA14 Gene Cassette Integrated at a Secondary Site in a Resistance Plasmid of Uropathogenic Escherichia coli from Nigeria. Antimicrobial Agents and Chemotherapy, 2002, 46, 2054-2055.	3.2	24
96	Vaccine-Linked Chemotherapy Approach: Additive Effects of Combining the Listeria monocytogenes-Based Vaccine Lm3Dx_NcSAG1 With the Bumped Kinase Inhibitor BKI-1748 Against Neospora caninum Infection in Mice. Frontiers in Veterinary Science, 0, 9, .	2.2	2